SG165152A1 - Chemokine receptor antagonists and methods of use thereof - Google Patents

Chemokine receptor antagonists and methods of use thereof

Info

Publication number
SG165152A1
SG165152A1 SG200603354-2A SG2006033542A SG165152A1 SG 165152 A1 SG165152 A1 SG 165152A1 SG 2006033542 A SG2006033542 A SG 2006033542A SG 165152 A1 SG165152 A1 SG 165152A1
Authority
SG
Singapore
Prior art keywords
methods
receptor antagonists
chemokine receptor
activation
treating
Prior art date
Application number
SG200603354-2A
Other languages
English (en)
Inventor
Jay R Luly
Yoshisuke Nakasato
Etsuo Ohshima
Geraldine C B Harriman
Kenneth G Carson
Shomir Ghosh
Amy M Elder
Karen M Mattia
Original Assignee
Millennium Pharm Inc
Kyowa Hakko Kogyo Co Ltd 2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/989,086 external-priority patent/US20020169155A1/en
Application filed by Millennium Pharm Inc, Kyowa Hakko Kogyo Co Ltd 2 filed Critical Millennium Pharm Inc
Publication of SG165152A1 publication Critical patent/SG165152A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
SG200603354-2A 2001-11-21 2002-11-13 Chemokine receptor antagonists and methods of use thereof SG165152A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/989,086 US20020169155A1 (en) 1998-09-04 2001-11-21 Chemokine receptor anagonists and methods of use therefor

Publications (1)

Publication Number Publication Date
SG165152A1 true SG165152A1 (en) 2010-10-28

Family

ID=32713949

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011011095A SG195393A1 (en) 2001-11-21 2002-11-13 Chemokine receptor antagonists and methods of use thereof
SG200603354-2A SG165152A1 (en) 2001-11-21 2002-11-13 Chemokine receptor antagonists and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011011095A SG195393A1 (en) 2001-11-21 2002-11-13 Chemokine receptor antagonists and methods of use thereof

Country Status (24)

Country Link
EP (3) EP1448566B3 (zh)
JP (5) JP4889920B2 (zh)
KR (3) KR100952767B1 (zh)
CN (3) CN1585772B (zh)
AR (2) AR037394A1 (zh)
AT (1) ATE320431T1 (zh)
AU (1) AU2002352772B2 (zh)
BR (1) BR0213633A (zh)
CA (1) CA2467672C (zh)
CY (1) CY1107243T1 (zh)
DE (2) DE60209937D1 (zh)
DK (1) DK1448566T5 (zh)
ES (2) ES2260497T7 (zh)
HK (2) HK1063789A1 (zh)
IL (3) IL161669A0 (zh)
MY (2) MY142646A (zh)
NO (1) NO328166B1 (zh)
NZ (3) NZ532827A (zh)
PL (2) PL403800A1 (zh)
PT (1) PT1448566E (zh)
SG (2) SG195393A1 (zh)
SI (1) SI1448566T1 (zh)
TW (1) TWI308568B (zh)
ZA (1) ZA200403530B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
EP2229356B1 (en) * 2007-12-03 2011-10-12 Novartis AG 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (zh) *
WO1996031469A1 (en) * 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
WO1999037651A1 (en) * 1998-01-21 1999-07-29 Millenium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2001009138A2 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2001009137A1 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5250634B2 (zh) 1971-08-23 1977-12-26
JPS61152673A (ja) 1984-12-26 1986-07-11 Kyowa Hakko Kogyo Co Ltd ジベンズ〔ｂ，ｅ〕オキセピン誘導体の製造法
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
DE68916699T2 (de) 1988-04-28 1994-12-01 Schering Corp Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
AU2028892A (en) 1991-05-23 1992-12-30 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
EP0524784A1 (en) 1991-07-23 1993-01-27 Schering Corporation Benzopyrido piperidylidene compounds as PAF antagonists
DK0669979T3 (da) 1992-11-10 2006-03-06 Genentech Inc C-C CKR-1, kemokinreceptor
HUP9901652A3 (en) * 1995-12-15 2000-04-28 Novo Nordisk As Use of piperidine-carboxylic acid derivatives for producing pharmaceutical compositions suitable for reducing blood glucose
AU2331199A (en) * 1998-09-04 2000-03-27 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
DE60026556T2 (de) 1999-10-20 2006-12-14 Kingspan Holdings (Irl) Ltd., Kingscourt Zellulärer kunststoff auf basis phenolharz
TW503427B (en) 2000-07-25 2002-09-21 Koninkl Philips Electronics Nv Display tube comprising a mask with vibration damping means
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
DE102011084910A1 (de) 2011-10-20 2013-04-25 Wobben Properties Gmbh Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (zh) *
WO1996031469A1 (en) * 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
WO1999037651A1 (en) * 1998-01-21 1999-07-29 Millenium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20020119973A1 (en) * 1998-01-21 2002-08-29 Jay R. Luly Chemokine receptor antagonists and methods of use therefor
WO2001009138A2 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2001009137A1 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
PL403800A1 (pl) 2013-08-19
ES2260497T7 (es) 2009-11-05
EP1688418B1 (en) 2017-03-15
CN1585772A (zh) 2005-02-23
CN104031054A (zh) 2014-09-10
EP2286811B1 (en) 2012-09-05
TW200303197A (en) 2003-09-01
CY1107243T1 (el) 2012-11-21
SG195393A1 (en) 2013-12-30
EP1688418A2 (en) 2006-08-09
BR0213633A (pt) 2004-08-24
ES2396186T3 (es) 2013-02-19
DK1448566T5 (da) 2009-08-03
TWI308568B (en) 2009-04-11
CA2467672A1 (en) 2003-06-05
MY146601A (en) 2012-08-30
AU2002352772B2 (en) 2006-10-26
KR20070118146A (ko) 2007-12-13
JP2005510565A (ja) 2005-04-21
CA2467672C (en) 2011-06-28
NZ596484A (en) 2013-05-31
JP4889920B2 (ja) 2012-03-07
EP1448566A2 (en) 2004-08-25
HK1154504A1 (en) 2012-04-27
MY142646A (en) 2010-12-15
ES2260497T3 (es) 2006-11-01
IL181191A (en) 2012-10-31
DK1448566T3 (da) 2006-07-31
PL217918B1 (pl) 2014-09-30
JP2013209393A (ja) 2013-10-10
CN1911930A (zh) 2007-02-14
EP1448566B3 (en) 2009-04-08
EP1448566B1 (en) 2006-03-15
NZ585746A (en) 2011-12-22
AU2002352772A1 (en) 2003-06-10
JP2015083577A (ja) 2015-04-30
AR037394A1 (es) 2004-11-10
JP2016138122A (ja) 2016-08-04
EP1688418A3 (en) 2008-05-14
ATE320431T1 (de) 2006-04-15
KR20040064283A (ko) 2004-07-16
IL161669A (en) 2010-12-30
IL181191A0 (en) 2007-07-04
DE60209937T2 (de) 2006-11-30
IL161669A0 (en) 2004-09-27
CN1585772B (zh) 2014-06-04
PT1448566E (pt) 2006-08-31
JP2010229136A (ja) 2010-10-14
KR100919346B1 (ko) 2009-09-25
ZA200403530B (en) 2005-07-28
AR090829A2 (es) 2014-12-10
JP5878494B2 (ja) 2016-03-08
PL369599A1 (en) 2005-05-02
NO328166B1 (no) 2009-12-21
HK1063789A1 (en) 2005-01-14
EP2286811A1 (en) 2011-02-23
DE60209937T4 (de) 2009-10-29
KR101001092B1 (ko) 2010-12-14
NO20042500L (no) 2004-06-15
NZ532827A (en) 2007-09-28
DE60209937D1 (de) 2006-05-11
KR20100010952A (ko) 2010-02-02
JP5936669B2 (ja) 2016-06-22
SI1448566T1 (sl) 2006-08-31
KR100952767B1 (ko) 2010-04-14

Similar Documents

Publication Publication Date Title
HK1044333A1 (zh) 趨化因子受體拮抗劑及其使用方法
ATE309249T1 (de) Chemokin rezeptor antagonisten und verwndung
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2005042516A3 (en) Ligands of melanocortin receptors and compositions and methods related thereto
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
HK1038926A1 (en) Crf receptor antagonists and methods relating thereto
HK1038925A1 (en) Crf receptor antagonists and methods relating thereto crf
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
WO2001009119A3 (en) Chemokine receptor antagonists
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
WO2001009094A3 (en) Chemokine receptor antagonists and methods of use therefor
PT2266558T (pt) Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
EP1787984A3 (en) Azacyclic compounds for use in the treatment of serotonin related diseases